TOKYO – Swiss pharmaceutical giant Roche will soon seek approval in Japan of its COVID-19 reagent and seasonal influenza virus, Nikkei has been known.
The reagent can stumble upon the virus with a high degree of accuracy when combined with Roche’s verification apparatus belonging to medical facilities and verification companies, and also reduces the burden on patients and medical preparation for the double risk of COVID-19 and winter flu.
The reagent is used for polymerase or PCR chain reaction tests. Roche Diagnostics, Roche’s Japanese unit, will soon register an application for the drug with the Ministry of Health, Labour and Social Services.
Roche has already been implemented in the United States. On September 3, the U. S. Food and Drug Administration granted the company emergency use authorization from the regulator.
The new reagent will be used with the Control Device Cobas 6800 and Cobas 8800 developed by Roche. A mucus pattern of the nose and throat is taken as a pattern. The reagent may run into COVID-19, as well as influenza A and influenza B viruses with an unmarried pattern.
The verification team, along with the new reagent, can read about samples from up to 96 more people and only takes 3 hours to download the results.
The prices of test appliances are tens of millions of yen (hundreds of thousands of dollars) according to the unit. Some hospitals and corporations such as H. U. Group Holdings own 40 devices combined nationwide.
Due to limited availability, the new reagent is unlikely to be used for the initial test; However, it is most likely used when superior accuracy is required, for example, to re-analyze others suspected of being inflamed and those who are already inflamed. hospitalized for illness.
Subscribe to our newsletters to get our stories right in your inbox.
You want an Array subscription. .